Genomic Health (GHDX) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Jefferies Raises price Target on Genomic Health (GHDX) Following Initial 2016 Outlook
February 11, 2016 10:05 AM ESTJefferies reiterated a Hold rating on Genomic Health Inc. (NASDAQ: GHDX), and raised the price target to $25.00 (from $24.00). Consistent with commentary last month, GHDX reiterated its 2016 revenue outlook ($328M mid-pt), which implies a sharp growth acceleration on the back of full-year contributions from recent... More
Piper Jaffray Cuts Price Target on Genomic Health (GHDX) After 4Q Reports In-Line with Preliminary Results
February 11, 2016 9:15 AM ESTPiper Jaffray reiterated a Neutral rating on Genomic Health Inc. (NASDAQ: GHDX), and cut the price target to $31.00 (from $32.00), following the company's 4Q earnings report. Genomic Health announced 4Q15 revenue growth of 7.8% yoy to $74.5M, slightly above preliminary results ($73M-$74M). Management attributes... More
